<DOC>
	<DOCNO>NCT00638911</DOCNO>
	<brief_summary>The aim therapeutic observation demonstrate efficacy safety telmisartan telmisartan HCTZ treatment patient mild-to-moderate essential hypertension normal condition use market launch .</brief_summary>
	<brief_title>Using Telmisartan Alone Combination Telmisartan -HCTZ Treatment Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>Study 502.465 ( NCT00638911 ) plan conduct 6 independent substudies vary country participation . One study database , data management plan TSAP plan exist precludes baseline outcome analysis .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age 18 year , mildtomoderate essential hypertension value mean morning seat diastolic BP 90 mmHg less 109 mmHg mean morning seat systolic BP 140 mmHg less 180 mmHg 1. newly diagnose patient 2. patient fail reach target blood pressure le 140 90 current antihypertensive treatment Exclusion criterion : 1 . Premenopausal woman use adequate contraception pregnant nursing 2 . Cholestasis biliary obstructive disorder 3 . Severe hepatic impairment 4 . Severe renal impairment creatinine clearance le 30 ml pro min 5 . Refractory hypokalaemia hypercalcaemia 6 . Known hypersensitivity component formulation Micardis/Micardis Plus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>